HIV/AIDS

7.5.2 Second-line ART for children (including adolescents)

Consolidated ARV guidelines, June 2013


Key research gaps

More evidence is needed to inform the choice of second-line regimens for young children for whom an LPV/r-based first-line regimen has failed. Validation studies to assess simplified dosing for ATV/r and DRV/r fixed-dose combinations are critical to ensure future effective alternatives. Innovative second-line strategies such as PI + integrase inhibitors or induction and maintenance using PI/r monotherapy among children should also be investigated.

Share